Pathogenics Inc. is a privately held pharmaceutical company that is developing the clinical-stage, novel anti-infective/anti-inflammatory medicine N-Chlorotaurine (NCT) for the treatment of mild to severe COVID-19 cases and other infections.
The Company’s core operational strengths are the expertise and successful track records of its business management and scientific development team.